Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167446545> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W3167446545 endingPage "566" @default.
- W3167446545 startingPage "566" @default.
- W3167446545 abstract "<h3>Background</h3> Hereditary transthyretin-mediated (hATTR) amyloidosis, a rare, multi-systemic, life-threatening disease, causes neurologic and cardiac dysfunction, leading to impaired functional status and declining ability to perform activities of daily living (ADLs). <h3>Objectives</h3> To analyze the impact of patisiran on ADLs and functional status in the Phase 3 APOLLO study. <h3>Methods</h3> APOLLO was a randomized, placebo-controlled study of patisiran in patients with hATTR amyloidosis with polyneuropathy (NCT01960348). ADL/functional status assessments included: Rasch-built Overall Disability Scale (R-ODS), Karnofsky Performance Status (KPS), the ADL subdomain of Norfolk QOL-DN (Norfolk ADL). Post-hoc analyses quantified patients with no change/improvement in these assessments at 18 months. <h3>Results</h3> APOLLO enrolled 225 patients worldwide with a mean age of 60.5 years, 74% male, and 43% with V30M transthyretin mutation. At baseline, patisiran and placebo groups had similar R-ODS, KPS, and Norfolk ADL scores. After 18 months, a higher proportion of patisiran-treated patients experienced no change/improvement in functional status and ADLs relative to placebo: R-ODS 49.3% vs 13.0% (odds ratio [OR] 6.5, 95% confidence interval [CI] 2.8 to 15.4), KPS 64.9% vs 42.9%, (OR 2.5, 95% CI 1.3 to 4.8), Norfolk ADL 56.2% vs 20.4% (OR 5.0, 95% CI 2.4 to 10.5). <h3>Conclusions</h3> In APOLLO, the largest randomized clinical study of patients with hATTR amyloidosis with polyneuropathy to date, patisiran preserved ability to perform ADLs and functional status for the majority of patients and demonstrated greater odds of stabilizing or improving these assessments compared to placebo." @default.
- W3167446545 created "2021-06-22" @default.
- W3167446545 creator A5005623896 @default.
- W3167446545 creator A5012385354 @default.
- W3167446545 creator A5015330548 @default.
- W3167446545 creator A5018046599 @default.
- W3167446545 creator A5033586858 @default.
- W3167446545 creator A5057744038 @default.
- W3167446545 creator A5061347020 @default.
- W3167446545 creator A5075723146 @default.
- W3167446545 creator A5080039638 @default.
- W3167446545 creator A5081059143 @default.
- W3167446545 creator A5086160598 @default.
- W3167446545 date "2021-07-01" @default.
- W3167446545 modified "2023-10-16" @default.
- W3167446545 title "P011. Impact of Patisiran on Activities of Daily Living and Functional Status in hATTR Amyloidosis" @default.
- W3167446545 doi "https://doi.org/10.1016/j.hrtlng.2021.03.066" @default.
- W3167446545 hasPublicationYear "2021" @default.
- W3167446545 type Work @default.
- W3167446545 sameAs 3167446545 @default.
- W3167446545 citedByCount "0" @default.
- W3167446545 crossrefType "journal-article" @default.
- W3167446545 hasAuthorship W3167446545A5005623896 @default.
- W3167446545 hasAuthorship W3167446545A5012385354 @default.
- W3167446545 hasAuthorship W3167446545A5015330548 @default.
- W3167446545 hasAuthorship W3167446545A5018046599 @default.
- W3167446545 hasAuthorship W3167446545A5033586858 @default.
- W3167446545 hasAuthorship W3167446545A5057744038 @default.
- W3167446545 hasAuthorship W3167446545A5061347020 @default.
- W3167446545 hasAuthorship W3167446545A5075723146 @default.
- W3167446545 hasAuthorship W3167446545A5080039638 @default.
- W3167446545 hasAuthorship W3167446545A5081059143 @default.
- W3167446545 hasAuthorship W3167446545A5086160598 @default.
- W3167446545 hasConcept C126322002 @default.
- W3167446545 hasConcept C142724271 @default.
- W3167446545 hasConcept C156957248 @default.
- W3167446545 hasConcept C1862650 @default.
- W3167446545 hasConcept C204787440 @default.
- W3167446545 hasConcept C27081682 @default.
- W3167446545 hasConcept C2775892965 @default.
- W3167446545 hasConcept C2779951007 @default.
- W3167446545 hasConcept C44249647 @default.
- W3167446545 hasConcept C71924100 @default.
- W3167446545 hasConcept C79544238 @default.
- W3167446545 hasConceptScore W3167446545C126322002 @default.
- W3167446545 hasConceptScore W3167446545C142724271 @default.
- W3167446545 hasConceptScore W3167446545C156957248 @default.
- W3167446545 hasConceptScore W3167446545C1862650 @default.
- W3167446545 hasConceptScore W3167446545C204787440 @default.
- W3167446545 hasConceptScore W3167446545C27081682 @default.
- W3167446545 hasConceptScore W3167446545C2775892965 @default.
- W3167446545 hasConceptScore W3167446545C2779951007 @default.
- W3167446545 hasConceptScore W3167446545C44249647 @default.
- W3167446545 hasConceptScore W3167446545C71924100 @default.
- W3167446545 hasConceptScore W3167446545C79544238 @default.
- W3167446545 hasIssue "4" @default.
- W3167446545 hasLocation W31674465451 @default.
- W3167446545 hasOpenAccess W3167446545 @default.
- W3167446545 hasPrimaryLocation W31674465451 @default.
- W3167446545 hasRelatedWork W14265451 @default.
- W3167446545 hasRelatedWork W15311529 @default.
- W3167446545 hasRelatedWork W16684663 @default.
- W3167446545 hasRelatedWork W2520082 @default.
- W3167446545 hasRelatedWork W4448858 @default.
- W3167446545 hasRelatedWork W6668650 @default.
- W3167446545 hasRelatedWork W6734634 @default.
- W3167446545 hasRelatedWork W8119474 @default.
- W3167446545 hasRelatedWork W941055 @default.
- W3167446545 hasRelatedWork W13713547 @default.
- W3167446545 hasVolume "50" @default.
- W3167446545 isParatext "false" @default.
- W3167446545 isRetracted "false" @default.
- W3167446545 magId "3167446545" @default.
- W3167446545 workType "article" @default.